Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT)
Latest Information Update: 06 Sep 2021
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms BENEFIT-OL
- Sponsors Actelion Pharmaceuticals
Most Recent Events
- 05 Aug 2019 New trial record